Outcomes and prediction of lethal recurrence after transoral robotic surgery for HPV+ head and neck cancer.

Authors

Devraj Basu

Devraj Basu

The University of Pennsylvania, Philadelphia, PA

Devraj Basu , David Shimunov , Roger B. Cohen , Alexander Lin , Samuel Swisher-McClure , John Nicholas Lukens , Joshua Bauml , Lee P. Hartner , Charu Aggarwal , Umamaheswar Duvvuri , Karthik Rajasekaran , Ara Chalian , Christopher Rassekh , Steven Cannady , Jason Newman , Bert W. O'Malley , Gregory S. Weinstein , Phyllis A. Gimotty , Robert Brody

Organizations

The University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, Univ of Pennsylvania Abramson Cancer Ctr, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, University of Maryland, Baltimore, MD, Univ of Pennsylvania School of Medcn, Philadelphia, PA, Penn Medicine, Philadelphia, PA

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Increasing use of transoral robotic surgery (TORS) for human papilloma virus-related (HPV+) head and neck squamous cell carcinomas (HNSCCs) is likely to impact recurrence patterns and outcomes. Profiling HPV+ HNSCC recurrences after TORS and identifying features predictive of lethal outcome would facilitate tailoring adjuvant therapy and guide surveillance post-therapy. This study uses long term follow-up of patients at the first institution to bring TORS into clinical use to describe the recurrence patterns, distinguish outcomes associated with distinct patterns, and create a risk model for lethal recurrence. Methods: This retrospective cohort study at a single academic tertiary center analyzed 634 consecutive, treatment-naïve HPV+ HNSCC patients receiving TORS and neck dissection for clinical features at presentation and pathologic traits identified by surgical resection. The main outcomes were distant metastatic recurrence (DMR) and locoregional recurrence (LRR). Multivariate logistic regression with backward stepwise elimination was used to identify features associated with recurrence. Results: 6.5% of patients developed DMR at a median of 12.4 months after surgery and had a 5-year overall survival (OS) of 52.5% (95% CI, 33.9%-68.2%), whereas the 6.2% patients developing LRR alone had 5-year OS of 83.3% (95% CI, 66.2%-92.2%; P =.01). After recurrence, 5-year progression-free survival was 24.7% (95% CI, 11.4%-40.7%) for DMR cases and 85.7% (95% CI, 65.1-94.6%) for cases with LRR alone (P <.001). Comparing recurrent cases to recurrence-free controls showed DMR to be independently associated with positive surgical margins (AOR 5.7; 95% CI, 2.1-15.7) and advanced clinical stage at presentation (AOR 6.5; 95% CI, 1.9-23.0). Positive margins increased DMR risk by 4.2-fold and reduced 5-year disease-free survival (P <.001) in early-stage cases (Table), which comprised 95% of the cohort. By contrast, isolated LRR was associated with failure to receive indicated adjuvant therapy and was usually controllable by salvage therapy. Conclusions: Based on the largest single institution cohort reported to date, long term oncologic outcomes for HPV+ HNSCCs after TORS are excellent overall. While DMR is often fatal, LRR is salvageable with durable disease control. In addition to standard staging criteria, positive margins indicate substantially higher risk of DMR but not LRR. A risk model for DMR that incorporates margin status after TORS is relevant for guiding clinical trial design and whole-body surveillance.

Risk model for DMR.

Advanced clinical stagePositive marginTotal patients
(N)
DMR
absent
(N)
DMR present
(N)
Risk DMR
(%)
Coefficient in modelaAdjusted odds ratio95% CIPvalue
NoNo270244269.6-[reference]--
NoYes2012840.01.86.32.3-16.7<.001
YesNo127541.71.96.72.0-22.6.002
YesYes0-------

a. Coefficient in logistic regression model. Intercept is -2.2

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6047)

DOI

10.1200/JCO.2021.39.15_suppl.6047

Abstract #

6047

Poster Bd #

Online Only

Abstract Disclosures